By Kate Rawson
When AstraZeneca PLC retooled its direct-to-consumer advertising last year, the reasons had nothing to do with market share. Instead, the company, along with most of its Big Pharma peers,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?